Mechanism underlying the effect of Fuhebeihua Recipe on the proliferation of CD133+HepG2 hepatoma stem cells and related autophagy proteins

doi:10.12307/2022.992

Abstract

Abstract: BACKGROUND: Hepatoma stem cells are key cells for the continuous development and high heterogeneity of liver cancer. At present, there is no research on Chinese medicine compound that targets hepatoma stem cell-related autophagy pathways. Therefore, it is very necessary to study Chinese medicine compound prescription to inhibit hepatoma stem cell autophagy.
OBJECTIVE: To investigate the effect and mechanism of Fuhebeihua Recipe on PI3K/AKT/mTOR pathway and related autophagy proteins in CD133+HepG2 hepatoma stem cells.
METHODS: CD133+HepG2 cells were selected by immunomagnetic bead method. CD133+HepG2 cells were treated with different volume fractions of Fuhebeihua Recipe-containing serum of 2%, 4%, 8%, and 16%. The cell proliferation activity was detected by CCK-8 assay. The best volume fraction of Fuhebeihua Recipe-containing serum was selected. CD133+HepG2 cells were divided into blank control group, serum control group, rapamycin group, and Fuhebeihua Recipe group. Cells were separately cultured with DMEM/F12 containing serum of 16%, serum-free DMEM/F12, DMEM/F12 containing 0.05% rapamycin, and DMEM/F12 with Fuhebeihua Recipe-containing serum of 16%. The percentage of CD133+HepG2 hepatoma stem cells was detected by flow cytometry in each group. The mRNA expression levels of PI3K, AKT, mTOR, LC3-II, and beclin-1 were detected by RT-PCR. The protein expression levels of PI3K, p-AKT, AKT, p-mTOR, mTOR, and LC3-II were detected by western blot assay. The expression levels of LC3 and LC3-II were detected by immunofluorescence in each group.
RESULTS AND CONCLUSION: (1) The Fuhebeihua Recipe-containing serum inhibited the proliferation of CD133+HepG2 cells, and the inhibitory effect was the most obvious when the volume fraction was 16% (P < 0.05). (2) Compared with serum control group and blank control group, the percentage of CD133+HepG2 cells reduced (P < 0.05); protein expression levels of PI3K, AKT, p-mTOR, mTOR, and LC3-II were significantly decreased (P < 0.05); mRNA expression levels of PI3K, AKT, mTOR, LC3-II, and Beclin-1 were significantly down-regulated (P < 0.05); the fluorescence signal intensities of LC3 and LC3-II were significantly down-regulated (P < 0.05) in the Fuhebeihua Recipe group and rapamycin group. (3) Compared with the rapamycin group, the protein expression levels of PI3K, p-Akt, AKT, p-mTOR, mTOR, and LC3-II in CD133+HepG2 cells were significantly down-regulated (P < 0.05); the mRNA expression levels of PI3K, AKT, mTOR, LC3-II, and Beclin-1 were significantly decreased (P < 0.05); the fluorescence signal intensities of LC3 and LC3-II were significantly decreased in the Fuhebeihua Recipe group (P < 0.05). (4) It is concluded that Fuhebeihua Recipe can inhibit autophagy and proliferation of hepatoma stem cells, and its mechanism is related to the inhibition of PI3K/AKT/mTOR signaling pathway.

Key words: hepatoma stem cells, Fuhebeihua Recipe, PI3K, AKT, mTOR, pathway, LC3, autophagy

CLC Number:

Li Zulong, Rong Zhen, Sun Hua, Jiang Ruiyuan, Zhong Xiaoting, Mo Chunmei. Mechanism underlying the effect of Fuhebeihua Recipe on the proliferation of CD133+HepG2 hepatoma stem cells and related autophagy proteins[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(31): 4988-4995.

Figures/Tables 10

References

[1] EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
[2] SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
[3] ZHANG X, MENG S, ZHANG R, et al. GP73-regulated oncolytic adenoviruses possess potent killing effect on human liver cancer stem-like cells. Oncotarget. 2016;7(20):29346-29358.
[4] LI X, HE S, MA B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 2020;19(1):12-16.
[5] DIKIC I, ELAZAR Z. Mechanism and medical implications of mammalian autophagy. Nat Rev Mol Cell Biol. 2018;19(6):349-364.
[6] GALLUZZI L, BRAVO-SAN PEDRO JM, Levine B, et al. Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat Rev Drug Discov. 2017;16(7):487-511.
[7] MATHEW R, WHITE E. Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev. 2011; 21(1):113-119.
[8] XU Z, HAN X, OU D, et al. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy. Appl Microbiol Biotechnol. 2020;104(2): 575-587.
[9] XIE Y, SHI X, SHENG K, et al. PI3K/Akt signaling transduction pathway, erythropoiesis and glycolysis in hypoxia (Review). Mol Med Rep. 2019; 19(2):783-791.
[10] GUERTIN DA, SABATINI DM. The pharmacology of mTOR inhibition.Sci Signal. 2009;2(67):pe24.
[11] 付彬.敷和备化方对肝癌干细胞的调控作用研究[D].南宁:广西中医药大学,2020.
[12] SONG Y, JANG J, SHIN TH, et al. Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. J Exp Clin Cancer Res. 2017;36(1):38-42.
[13] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
[14] VILLANUEVA A. Hepatocellular Carcinoma. N Engl J Med. 2019;380(15): 1450-1462.
[15] RAGHAV PK, MANN Z. Cancer stem cells targets and combined therapies to prevent cancer recurrence. Life Sci. 2021;277:119465.
[16] YANG ZF, NGAI P, HO DW, et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008;47(3):919-928.
[17] AGHAJANI M, MANSOORI B, MOHAMMADI A, et al. New emerging roles of CD133 in cancer stem cell: Signaling pathway and miRNA regulation. J Cell Physiol. 2019;234(12):21642-21661.
[18] TAKAMURA A, KOMATSU M, HARA T, et al. Autophagy-deficient mice develop multiple liver tumors. Genes Dev. 2011;25(8):795-800.
[19] LI J, YANG B, ZHOU Q, et al. Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis. 2013;34(6):1343-1351.
[20] CHANG Y, YAN W, HE X, et al. miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions. Gastroenterology. 2012;143(1):177-187.
[21] WU DH, JIA CC, CHEN J, et al. Autophagic LC3B overexpression correlates with malignant progression and predicts a poor prognosis in hepatocellular carcinoma. Tumour Biol. 2014;35(12):12225-12233.
[22] LAZOVA R, CAMP RL, KLUMP V, et al. Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis, and poor outcome. Clin Cancer Res. 2012;18(2):370-379.
[23] ZHOU Y, CHEN E, TANG Y, et al. miR-223 overexpression inhibits doxorubicin-induced autophagy by targeting FOXO3a and reverses chemoresistance in hepatocellular carcinoma cells. Cell Death Dis. 2019;10(11):843-847.
[24] ZHANG K, CHEN J, ZHOU H, et al. PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib. Cell Death Dis. 2018;9(3):312-318.
[25] LEE YG, JEON TI. Modulation of the Autophagy-lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules. Molecules. 2020; 25(7):1580.
[26] ISHIZAWA T, HASEGAWA K, AOKI T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008;134(7):1908-1916.
[27] LLOVET JM. Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol. 2004;7(6):431-441.
[28] CUCCHETTI A, PISCAGLIA F, CESCON M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013;59(2):300-307.
[29] 尹常健.中医药治疗肝癌的几个理论与实践问题[J].中西医结合肝病杂志,2019,29(2):112-113,117.
[30] 王磊,周荣耀.周荣耀补肾健健脾法治疗原发性肝癌经验[J].辽宁中医杂志,2014,41(2):2547-2548.